Misplaced Pages

Pegsunercept: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editContent deleted Content addedVisualWikitext
Revision as of 02:57, 17 November 2023 editEntranced98 (talk | contribs)Extended confirmed users, Pending changes reviewers, Rollbackers170,242 edits Importing Wikidata short description: "Chemical compound"Tag: Shortdesc helper← Previous edit Latest revision as of 06:59, 31 December 2023 edit undoWhywhenwhohow (talk | contribs)Autopatrolled, Extended confirmed users, Pending changes reviewers48,667 edits →top: infobox 
Line 30: Line 30:
<!-- Chemical data --> <!-- Chemical data -->
| C=502 | H=758 | N=154 | O=165 | S=16 | C=502 | H=758 | N=154 | O=165 | S=16
| molecular_weight = 12,103 g/mol (protein part)
}} }}
'''Pegsunercept''' is a ] for the treatment of ]. {{As of|2010|1}}, Phase II ]s have been completed.<ref>{{ClinicalTrialsGov|NCT00037700|Evaluation of the Efficacy of Combination Treatment With Anakinra and Pegsunercept in Improving Rheumatoid Arthritis}}</ref><ref>{{ClinicalTrialsGov|NCT00111423|Evaluating the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI)in Subjects With Rheumatoid Arthritis (RA)}}</ref><ref name="Furst">{{cite journal | vauthors = Furst DE, Fleischmann R, Kopp E, Schiff M, Edwards C, Solinger A, Macri M | title = A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritis | journal = The Journal of Rheumatology | volume = 32 | issue = 12 | pages = 2303–10 | date = December 2005 | pmid = 16331754 }}</ref> It is being developed by ]. '''Pegsunercept''' is a ] for the treatment of ]. {{As of|2010|1}}, Phase II ]s have been completed.<ref>{{ClinicalTrialsGov|NCT00037700|Evaluation of the Efficacy of Combination Treatment With Anakinra and Pegsunercept in Improving Rheumatoid Arthritis}}</ref><ref>{{ClinicalTrialsGov|NCT00111423|Evaluating the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI)in Subjects With Rheumatoid Arthritis (RA)}}</ref><ref name="Furst">{{cite journal | vauthors = Furst DE, Fleischmann R, Kopp E, Schiff M, Edwards C, Solinger A, Macri M | title = A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritis | journal = The Journal of Rheumatology | volume = 32 | issue = 12 | pages = 2303–10 | date = December 2005 | pmid = 16331754 }}</ref> It is being developed by ].

Latest revision as of 06:59, 31 December 2023

Chemical compound Pharmaceutical compound
Pegsunercept
Clinical data
Routes of
administration		subcutaneous injection
ATC code
  • none
Legal status
Legal status
  • investigational
Pharmacokinetic data
BioavailabilityN/A
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC502H758N154O165S16
Molar mass12103.46 g·mol
  (what is this?)  (verify)

Pegsunercept is a drug for the treatment of rheumatoid arthritis. As of January 2010, Phase II clinical trials have been completed. It is being developed by Amgen.

Similarly to etanercept, pegsunercept is a soluble tumor necrosis factor receptor. Pegsunercept is a PEGylated protein.

References

  1. Clinical trial number NCT00037700 for "Evaluation of the Efficacy of Combination Treatment With Anakinra and Pegsunercept in Improving Rheumatoid Arthritis" at ClinicalTrials.gov
  2. Clinical trial number NCT00111423 for "Evaluating the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI)in Subjects With Rheumatoid Arthritis (RA)" at ClinicalTrials.gov
  3. ^ Furst DE, Fleischmann R, Kopp E, Schiff M, Edwards C, Solinger A, Macri M (December 2005). "A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritis". The Journal of Rheumatology. 32 (12): 2303–10. PMID 16331754.
Immunosuppressive drugs / Immunosuppressants (L04)
Intracellular
(initiation)
Antimetabolites
Macrolides/
other IL-2 inhibitors
IMiDs
Intracellular
(reception)
IL-1 receptor antagonists
mTOR
Extracellular
Antibodies
Monoclonal
Serum target
(noncellular)
Cellular
target
Unsorted
Polyclonal
-cept (Fusion)
Unsorted
Cytokine receptor modulators
Chemokine
CSF
Erythropoietin
G-CSF (CSF3)
GM-CSF (CSF2)
M-CSF (CSF1)
SCF (c-Kit)
Thrombopoietin
Interferon
IFNAR (α/β, I)
IFNGR (γ, II)
IFNLR (λ, III)
  • See IL-28R (IFNLR) here instead.
Interleukin
TGFβ
TNF
Others
JAK
(inhibitors)
JAK1
JAK2
JAK3
TYK2
Others
Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

Categories: